A continuation protocol is not an ad tech spec. It is the paperwork that lets human research keep running once an initial approval or parent study expires. In US oversight, a principal investigator files a continuation with an institutional review board to extend an approved study. The same phrase also refers to rollover protocols that let participants keep receiving an investigational drug after the original trial closes.
Both exist because research routinely outlives its first approval. Under the Common Rule and the FDA’s IRB regulation, boards re-examine approved research ‘not less than once per year’. A continuation filing triggers that review; approval can extend the work for up to 364 days, while a full fresh review is called a renewal.
What the filing actually covers
A typical continuation reports:
- Participants enrolled, withdrawn and any adverse events
- Complaints, amendments and interim findings since last approval
- Current consent forms and recruitment materials
The board then asks whether the balance of risk and benefit still holds. If the approval lapses first, research activity must stop unless the IRB decides continuing treatment is in the best interest of already enrolled participants.
Where the rule came from
Annual continuing review goes back to the FDA’s 1981 IRB regulation and the 1991 Common Rule. The revised Common Rule, effective January 21, 2019, dropped the requirement for many minimal-risk studies, but FDA-regulated drug and device trials still need annual review. Post-trial access grew alongside: the Declaration of Helsinki added post-trial access language in 2000 and strengthened it in 2013, with a further revision adopted in October 2024.
Why it bites marketing
For most marketers, the term appears in health and pharma work. IRBs review recruitment advertising as part of the consent process. Changes to creative, landing pages or consent copy can go back to the board inside the next continuation, not on your media calendar.
Federal rules also bar sponsors from promoting an investigational drug as safe or effective, and FDA guidance asks recruitment ads to avoid promising outcomes, avoid calling an investigational product a ‘new treatment’ without saying it is experimental, and avoid making payment the dominant message.
Platform policies add another gate. Google has revised its prescription drug advertising rules in three markets, and LegitScript has passed 10,000 certified websites as a health ad gatekeeper, so health-adjacent campaigns face both research and platform review.
The AI sandbox is borrowing the same gate
The structure is spreading. Brazil’s ANPD let Synapse continue in its AI sandbox despite scoring 45 out of 100, below the 50-point floor its framework sets for continuing. The regulator imposed conditions and required formal go/no-go criteria for each cycle. That mirrors an IRB continuation: a periodic report, a scored review and a documented decision.
What to do about it now
First, do not fight the clock. If a trial recruitment campaign is running, map every creative or consent change to the next continuation window. Second, keep ad language conservative: avoid certainty, ‘new treatment’ claims without experimental framing, or payment-led messaging. Third, extend the same lens to AI sandboxes and other gated programmes. If you are in a pilot, build the periodic report and go/no-go evidence before the deadline, not after.
Source: PPC Land
